Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PRAX | US
3.80
6.22%
Healthcare
Biotechnology
30/06/2024
04/10/2024
64.94
67.21
67.50
62.23
Praxis Precision Medicines Inc. a clinical-stage biopharmaceutical company develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines Inc. was incorporated in 2015 and is based in Boston Massachusetts.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
69.5%1 month
76.0%3 months
61.5%6 months
60.3%-
-
2.45
0.00
0.00
-6.86
382.25
-
-132.26M
1.15B
1.15B
-
-10.50K
-
-54.30
-47.16
7.62
10.73
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
12.39
Range1M
13.65
Range3M
28.51
Rel. volume
0.99
Price X volume
16.93M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 13.09 | 1.26B | 0.23% | n/a | 53.59% |
Mesoblast Limited | MESO | Biotechnology | 10.81 | 1.26B | 23.40% | n/a | 24.76% |
Wave Life Sciences Ltd | WVE | Biotechnology | 8.41 | 1.24B | -4.76% | n/a | 656.70% |
Innoviva Inc | INVA | Biotechnology | 19.67 | 1.23B | 0.56% | 10.92 | 67.72% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 57.83 | 1.22B | 0.57% | 49.40 | 68.04% |
Fluent Inc | COGT | Biotechnology | 11.11 | 1.22B | 3.64% | n/a | 4.87% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 17.25 | 1.20B | 2.92% | n/a | -216.56% |
ARCUTIS BIOTHERAPEUTICS INC. | ARQT | Biotechnology | 10.02 | 1.17B | -2.05% | n/a | 111.34% |
Travere Therapeutics Inc. | TVTX | Biotechnology | 15.23 | 1.16B | 9.81% | n/a | 2662.08% |
Tyra Biosciences Inc. Common Stock | TYRA | Biotechnology | 22.04 | 1.16B | -1.52% | n/a | 1.70% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -6.86 | 0.76 | Cheaper |
Ent. to Revenue | 382.25 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.45 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 61.50 | 74.67 | Par |
Debt to Equity | 0.00 | -1.82 | Expensive |
Debt to Assets | 0.00 | 0.26 | Cheaper |
Market Cap | 1.15B | 3.73B | Emerging |